JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS
 QUICK SEARCH:   [advanced]


     


First published online February 17, 2009
J Nucl Med 2009, doi:10.2967/jnumed.108.057612
© 2009 by Society of Nuclear Medicine
This Article
Right arrow Full Text (Publish Ahead of Print[PDF])
Right arrow All Versions of this Article:
jnumed.108.057612v1
50/3/348    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McNamee, R. L.
Right arrow Articles by Mathis, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McNamee, R. L.
Right arrow Articles by Mathis, C. A.


Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements

Rebecca L. McNamee 1, Seong-Hwan Yee 1, Julie C. Price 1, William E. Klunk 2, Bedda Rosario 3, Lisa Weissfeld 3, Scott Ziolko 1, Michael Berginc 1, Brian Lopresti 1, Steven DeKosky 4, and Chester A. Mathis 1*

1 Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania
2 Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania
3 Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania
4 Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania

* To whom correspondence should be addressed. E-mail: mathca{at}upmc.edu.


   Abstract

The standardized uptake value ratio (SUVR, or summed tissue ratio) has been used effectively in Pittsburgh compound B (PiB) PET studies to distinguish subjects who have significant amyloid-{beta} deposition in their brain from those who do not. Relative to quantitative measurements, advantages of the SUVR are improved study feasibility and low test–retest variation; disadvantages include inherent bias (PiB retention overestimation) and potential for time-varying outcomes. The PiB SUVR has proven to be highly correlated with quantitative outcomes and to allow reliable detection of significant group differences (or effective contrasts). In this work, regional PiB SUVRs were examined across 9 time windows to select the window that provided the best trade-offs between bias, correlation, and effective contrast. Methods: A total of 40 dynamic PiB PET studies were performed on controls (n = 16), patients with Alzheimer disease (AD; n = 11), and patients with mild cognitive impairment (MCI; n = 13) (555 MBq [15 mCi], 90-min scan, and arterial blood sampling). The SUVR was computed for five 20-min and four 30-min windows that spanned the 30- to 90-min postinjection period. The SUVRs were compared with Logan graphical distribution volume ratio (DVR) measurements (35–90 min), determined with arterial blood as input and without arterial blood as input (cerebellum as reference). Results: Greater correlation and more bias were generally observed for the SUVR measurement at later times than at earlier times (relative to DVR). The effective contrast between the control and AD PiB SUVRs was slightly better for earlier data than for later data. The temporal dynamics of the SUVR measurement indicated greater stability in the measurement at 40 min after injection. Conclusion: The 50- to 70-min time window provided a good compromise between physiologic validity, stability, sensitivity, and clinical feasibility across the control, MCI, and AD subject data examined in this study. The 40- to 60-min period demonstrated many advantages and should be used in studies limited by low injected dose. Although more biased than the 40- to 60-min SUVR, the 50- to 70-min SUVR was thought to be optimal because of greater measurement stability, which may prove to be important for longitudinal multisite studies performed in control, MCI, and AD subjects that are not dose-limited.

Key Words: Pittsburgh compound B, PiB, SUV, SUVR, distribution volume ratio, DVR, PET




This article has been cited by other articles:


Home page
JNMHome page
N. Nelissen, K. Van Laere, L. Thurfjell, R. Owenius, M. Vandenbulcke, M. Koole, G. Bormans, D. J. Brooks, and R. Vandenberghe
Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease
J. Nucl. Med., August 1, 2009; 50(8): 1251 - 1259.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2009 by the Society of Nuclear Medicine.